RecruitingPhase 2NCT05633615
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Brian T HessSWOG Cancer Research Network
- Intervention
- Axicabtagene Ciloleucel(biological)
- Enrollment
- 396 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2030
Study locations (30)
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
- Highlands Oncology Group, Springdale, Arkansas, United States
- UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
- UCI Health Laguna Hills, Laguna Hills, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- UCSF Medical Center-Parnassus, San Francisco, California, United States
- UF Health Cancer Institute - Gainesville, Gainesville, Florida, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
- Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05633615 on ClinicalTrials.govOther trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07162012Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive LymphomaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE2NCT06846463Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+Virginia Commonwealth University
- RECRUITINGPHASE3NCT06929624A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaSuzhou Suncadia Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT06830031Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell LymphomaShanghai Exuma Biotechnology Ltd.
- RECRUITINGNCT07198230Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell LymphomaTing YANG
- RECRUITINGPHASE2NCT07254754Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- RECRUITINGPHASE3NCT06522555The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRuijin Hospital
- RECRUITINGPHASE2NCT05934448Pembro Plus CAR T-cell Therapy in R/R in PMBCLJennifer Crombie, MD
See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma →